Prognostic indicators of survival in sinonasal extranodal natural killer/T-cell lymphoma.
ENKTL
NK/T-cell lymphoma
population database SEER
prognostic factors
sinonasal
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
13
09
2018
revised:
28
12
2018
accepted:
04
02
2019
pubmed:
26
2
2019
medline:
31
1
2020
entrez:
26
2
2019
Statut:
ppublish
Résumé
Extranodal natural killer/T-cell lymphoma (ENKTL) is a highly aggressive tumor of the sinonasal tract associated with poor overall survival (OS). This study expands upon epidemiologic, prognostic, and treatment factors for OS and disease-specific survival (DSS), incorporating newly accessible chemotherapy data. Retrospective population-based cohort study performed on cases of sinonasal ENKTL identified through the Surveillance, Epidemiology, and End Results database. Univariate Kaplan-Meier analysis and subsequent multivariate Cox-regression analysis were performed to evaluate prognostic and treatment variables for OS and DSS. Four hundred and sixty cases of sinonasal ENKTL were identified. Five-year OS and DSS were 46% and 56%, respectively. On multivariate analysis, higher Ann Arbor stage was associated with worse OS (P < 0.001) and DSS (P < 0.001), whereas administration of radiotherapy was associated with improved OS (P < 0.001) and DSS (P = 0.001). Additionally, a higher age at diagnosis was associated with reduced OS (P = 0.024). Chemotherapy was associated with improved OS (P < .01) and DSS (P = .04) for Ann Arbor stage I disease. Surgery was not associated with improved survival. This represents the first study to investigate the use of chemotherapy for the treatment of sinonasal ENKTL using population-based analysis. Radiation therapy and chemotherapy significantly improve survival in all Ann Arbor stage patients and early-stage patients, respectively. Early-stage disease is significantly associated with improved survival. With no established treatment regimen for sinonasal ENKTL, these findings suggest combination chemoradiation is an effective therapy for prolonged survival, especially in early stages of disease. 3 Laryngoscope, 129:2675-2680, 2019.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2675-2680Informations de copyright
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Barnes L, Eveson J, Reichart P, Sidranksi D. World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2005.
Dubal PM, Dutta R, Vazquez A, Patel TD, Baredes S, Eloy JA. A comparative population-based analysis of sinonasal diffuse large B-cell and extranodal NK/T-cell lymphomas. Laryngoscope 2015;125:1077-1083.
Aozasa K, Takakuwa T, Hongyo T, Yang WI. Nasal NK/T-cell lymphoma: epidemiology and pathogenesis. Int J Hematol 2008;87:110-117.
Hsieh PP, Tung CL, Chan AB, et al. EBV viral load in tumor tissue is an important prognostic indicator for nasal NK/T-cell lymphoma. Am J Clin Pathol 2007;128:579-584.
Vazquez A, Khan MN, Blake DM, Sanghvi S, Baredes S, Eloy JA. Extranodal natural killer/T-Cell lymphoma: a population-based comparison of sinonasal and extranasal disease. Laryngoscope 2014;124:888-895.
Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood 2018;131:2528-2540.
Kommalapati A, Tella SH, Ganti AK, Armitage JO. Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States. Clin Lymphoma Myeloma Leuk 2018;18:475-479.
Crane GM, Duffield AS. Hematolymphoid lesions of the sinonasal tract. Semin Diagn Pathol 2016;33:71-80.
Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181-189.
Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004;100:366-375.
Wu XC, Andrews P, Chen VW, Groves FD. Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: anatomic site and histology differences. Cancer Epidemiol 2009;33:337-346.
Neves MC, Lessa MM, Voegels RL, Butugan O. Primary non-Hodgkin's lymphoma of the frontal sinus: case report and review of the literature. Ear Nose Throat J 2005;84:47-51.
Huang YH, Wu QL, Zong YS, Feng YF, Hou JH. Nasopharyngeal extranodal NK/T-cell lymphoma, nasal type: retrospective study of 18 consecutive cases in Guangzhou, China. Int J Surg Pathol 2011;19:51-61.
Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol 2012;96:617-623.
Tan L. Lymphomas involving Waldeyer's ring: placement, paradigms, peculiarities, pitfalls, patterns and postulates. Ann Acad Med Singapore 2004;33:15S-26S.
Salplahta D, Comanescu MV, Anghelina F, Ionita E, Mogoanta CA, Anghelina L. Non-Hodgkin lymphomas of Waldeyer's ring. Rom J Morphol Embryol 2012;54:1057-1060.
Logsdon MD, Ha CS, Kavadi VS, Cabanillas F, Hess MA, Cox JD. Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997;80:477-488.
Varelas AN, Eggerstedt M, Ganti A, Tajudeen BA. Epidemiologic, prognostic, and treatment factors in sinonasal diffuse large B-cell lymphoma. Laryngoscope 2018. https://doi.org/10.1002/lary.27639.
Vargo JA, Patel A, Glaser SM, et al. The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer/T-cell lymphoma, nasal type, in the United States. Cancer 2017;123:3176-3185.